EULAR responses observed with etanercept (ETA), adalimumab (ADA), and infliximab (INF) at 1, 2, 3, and 4 years.
| EULAR Responses | Adalimumab | Etanercept | Infliximab | p (chi-square test) | |||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | ||
| 1 year | |||||||
| None | 52 | (25.7) | 31 | (16.6) | 33 | (20.2) | < 0.01 ETA vs ADA |
| Moderate | 89 | (44.0) | 73 | (37.8) | 75 | (46.0) | < 0.01 ETA vs INF |
| Good | 61 | (30.2) | 89 | (46.1) | 55 | (33.7) | < 0.01 ETA vs ADA |
| 2 years | |||||||
| None | 31 | (20.8) | 26 | (16.9) | 18 | (14.5) | NS |
| Moderate | 50 | (33.5) | 49 | (32.0) | 52 | (41.9) | < 0.01 ETA vs INF |
| Good | 68 | (45.6) | 78 | (50.9) | 54 | (43.5) | NS |
| 3 years | |||||||
| None | 25 | (19.5) | 12 | (9.1) | 14 | (14.1) | < 0.01 ETA vs ADA |
| Moderate | 46 | (35.9) | 43 | (32.8) | 38 | (38.3) | NS |
| Good | 57 | (44.5) | 76 | (58.0) | 47 | (47.4) | NS |
| 4 years | |||||||
| None | 80 | (39.6) | 49 | (23.2) | 56 | (33.1) | < 0.01 ETA vs ADA or INF |
| Moderate | 62 | (30.6) | 54 | (25.5) | 54 | (31.9) | NS |
| Good | 60 | (29.7) | 108 | (51.1) | 59 | (34.9) | < 0.01 ETA vs ADA or INF |
EULAR: European League Against Rheumatism; NS: not significant.